MERIBANKBIOTECH
宣捷幹細胞生技股份有限公司
MERIBANKBIOTECH is a Taiwan Emerging Stock Board biotechnology company; its most advanced asset is UMC119-06-05 (Phase 1 / Phase 2; active not recruiting, Pathologic Processes), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| UMC119-06-05 | — | Phase 1 / Phase 2; active not recruiting | Pathologic Processes | Taiwan | 2024-07-15 | Trial registry |
Key events
- Business update (company filing)
Related Drugnews articles
No related articles in this language.